产品名称
右旋糖酐,
InChI key
JAQUASYNZVUNQP-PVAVHDDUSA-N
InChI
1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m1/s1
SMILES string
CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc4ccc(O)cc34
form
solid
optical activity
[α]/D ≥+54°
color
white to off-white
mp
≥195 °C
solubility
saline: soluble(lit.)
storage temp.
2-8°C
Quality Level
Gene Information
human ... GRIN2A(2903)
rat ... Grin2a(24409)
Application
CYP2D6 O-Demethyl metabolite of dextromethorphan
Dextrorphan has been studies as an N-methyl-D-aspartate (NMDA) receptor antagonist in Xenopus oocytes and hippocampal neuron cultures.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
Preparation Note
Dextrorphan is soluble in water.
Jaydeep Yadav et al.
Drug metabolism and disposition: the biological fate of chemicals, 47(7), 732-742 (2019-05-03)
Nonspecific drug partitioning into microsomal membranes must be considered for in vitro-in vivo correlations. This work evaluated the effect of including lipid partitioning in the analysis of complex TDI kinetics with numerical methods. The covariance between lipid partitioning and multiple
Ihab R Kamel et al.
Journal of neurosurgical anesthesiology, 20(4), 241-248 (2008-09-25)
Ketamine, an intravenous anesthetic and a major drug of abuse, is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Ketamine's enantiomer, S(+)-ketamine, acts stereoselectively on neuronal NMDA receptors. The purpose of this in vitro study was to compare the direct effects of
F Girardin et al.
Journal of viral hepatitis, 19(8), 568-573 (2012-07-06)
Liver kidney microsomal type 1 (LKM-1) antibodies have been shown to decrease the CYP2D6 activity in vitro and are present in a minority of patients with chronic hepatitis C infection. We investigated whether LKM-1 antibodies might reduce the CYP2D6 activity
Chris G Parsons et al.
Methods in molecular biology (Clifton, N.J.), 403, 15-36 (2008-10-02)
Electrophysiological techniques can be used to great effect to help determine the mechanism of action of a compound. However, many factors can compromise the resulting data and their analysis, such as the speed of solution exchange, expression of additional ion
XiaoMei Zhuang et al.
Biochemical pharmacology, 121, 67-77 (2016-09-27)
Icotinib (ICO), a novel small molecule and a tyrosine kinase inhibitor, was developed and approved recently in China for non-small cell lung cancer. During screening for CYP inhibition potential in human liver microsomes (HLM), heterotropic activation toward CYP3A5 was revealed.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持